BioSpace News Archive

DTx Pharma, Inc., a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced the appointment of Denise Bevers as Chief Operating Officer.

Data Marks the First Proof of Concept for a BiTE® Molecule in Thoracic Malignancy and Further Demonstrates Potential of BiTE® Immuno-Oncology Platform in Solid Tumors

Study Examines Plasma-Based Proteomic Profiling as a Clinically Insightful Tool for Oncologists to Identify New Targets in Overcoming Treatment Resistance

DKK1-high Anti-PD-1/PD-L1 Refractory Patients Treated with DKN-01 Plus Pembrolizumab Had Longer PFS and OS as compared to DKK1-low Patients

AMO Pharma Limited announced that the U.S. Food and Drug Administration has granted a Rare Pediatric Disease designation to AMO-Pharma for AMO-02, the company’s investigational therapy in development for the treatment of congenital myotonic dystrophy.

The comprehensive PAD program within EXPLORER continues to generate new findings that may shift the way symptomatic and chronic patients are managed

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that the Phase 3 CARDINAL study of bardoxolone methyl in patients with chronic kidney disease caused by Alport syndrome met its primary and key secondary endpoints at the end of Year 2.

Ra Medical Systems, Inc. announces a one-day DABRA Summit, during which participants will have the opportunity to provide input on the design features and enhancements for the Company’s next-generation DABRA catheters.

TherapeuticsMD, Inc., an innovative, leading women’s healthcare company, reported financial results for the third quarter ended September 30, 2020.

INmune Bio, Inc., a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced that the first patient has been dosed in its Phase 2 clinical trial evaluating Quellor™ for the treatment of pulmonary complications from COVID-19.